Clinical intelligence
for oncology practices

Turning fragmented patient records into clinical intelligence.

The problem

Patient records can’t answer clinical questions

The patient record is there. But it is scattered across years of PVS entries, scanned reports, PDFs and local spreadsheets.

These systems were built to document one patient encounter at a time, not to evaluate a study protocol across an entire patient panel.

The solution

Mosaic unlocks the clinical record for AI

Mosaic runs locally alongside the software already in use. It captures patient context, documents and scans and turns them into a structured, source-linked patient representation.

No replacement EHR. No second documentation workflow. No interface to every legacy system.

Understand the patient

From fragmented entries to one clinical history

Mosaic reconstructs diagnoses, biomarkers, treatments, progression events and therapy lines from the systems clinicians already use. It connects events across time, resolves information from different documents and preserves the evidence behind every finding. The result is a clinical representation that can be searched, reviewed and used by AI.

CGM TurboMed — [Patientenakte]×
DateiBearbeitenAnsichtExtras?
Patientin: M., Ingrid — *03.06.1964 — Fall-Nr. 0341
DATUMARTEINTRAG
04.02ANAMKnoten OQ re. Mamma seit ~6 Wo, schmerzlos.
11.02SCANPDFPathologie_Befund.pdf — Bilddatei, 3 Seiten
14.02BEFStaging-CT: ossäre Filiae LWK3METASTASES 98.4%.
20.02RPLetrozol 2,5 mg 1-0-0THERAPY_1L 99.3% — Denosumab 120 mg s.c. q4w.
06.03LABORBlutbild o. B. — CEA 3,1 ng/ml, CA 15-3 28 U/ml.
19.04BRIEFArztbrief Brustzentrum — Verlaufskontrolle empfohlen.
02.05VERLProgress unter 1LTHERAPY_LINE 99.1% — CT: Größenzunahme LWK3PROGRESSION 97.8%, neue Läsion Leber Seg. VIINEW_LESION 96.4%.
02.05PLANUmstellung auf T-DXdNEXT_THERAPY 98.6% geplant, Start nach Tumorkonferenz 09.05MTB_DATE 97.1%.
09.05VERLTumorkonferenz: Empfehlung bestätigt, Beginn 2L nach Port-Anlage.
14.05RPTrastuzumab-Deruxtecan 5,4 mg/kg q3w — Antiemese nach Schema.
14.05LABORLVEF 61 % (Echo), Krea 0,8 mg/dl, GFR > 90.
04.06VERLZyklus 2 — gute Verträglichkeit, keine Pneumonitis-Zeichen.
25.06BEFCT Thorax/Abdomen: Regredienz der Leberläsion.
16.07VERLZyklus 4 — ECOG 1, Fatigue Grad 1.
06.08LABORBlutbild: Hb 11,2 g/dl, Thrombozyten 187/nl.
27.08BRIEFRadiologie: Verlaufskontrolle in 3 Monaten empfohlen.
17.09VERLZyklus 7 — Therapie unverändert fortgeführt.
08.10TERMNächster Termin: 29.10, Infusion + Labor.
1.998 Einträge — 5 Jahre VerlaufF1 Hilfe
Mosaicreading the screenpatient history updated from 7 source-linked findings
Query the panel

Ask one clinical question across every patient record

Mosaic translates study protocols and clinical questions into structured logic and evaluates them against the available patient histories.

The result shows
Patients who are likely to matchCriteria that are confirmed, contradicted or missingRecords that require manual reviewThe exact evidence behind every assessment
MosaicTrial feasibility · DESTINY-Breast-XXPanel · 1,198 patients
PDFDESTINY-Breast-XX_Protocol_v2.1.pdf288 pages
How many of our patients could qualify for this study?
Thought for 9s
Searched the patient panel1,198 patients19 criteria checked, every match linked to its source entry

4 patients likely match. 6 more need a record review. I flagged what is missing for each.

PatientWhy it matchesEvidence
PSD-A7F3HER2 3+ · metastatic · progression 08.05verify4 sources
PSD-C2E8HER2 amplified · liver progression · 1 prior line5 sources
PSD-F8B2HER2 3+ · progressive diseaseverify3 sources
PSD-K1D4HER2+ · metastatic · progression after 1L6 sources
Show the 6 that need reviewOpen PSD-A7F3 timelineDraft the feasibility reply
Ask about the panel…
Mosaic Clinical
From answer to action

Mosaic does more than search the record

Once Mosaic can understand the patient history, the same intelligence can support the workflows around it.

01

Study feasibility

Evaluate a protocol against the available patient panel and estimate the reviewable cohort.

The team decidesCan we run this study?
02

Patient identification

Surface patients who may qualify, with each criterion marked as confirmed, contradicted or missing.

The team decidesWho should we review?
03

Therapy-line reconstruction

Reconstruct prescriptions, progression events and treatment changes as one cited sequence.

The team decidesIs the treatment history complete?
04

Screening readiness

Track required examinations, eligibility windows and missing evidence before enrolment.

The team decidesWhat still needs to be completed?
05

Oncology reporting

Prepare structured registry and study fields from the longitudinal patient history.

The team decidesWhat is ready for submission?
06

Longitudinal record review

Summarise what changed, what remains unresolved and which records require manual follow-up.

The team decidesWhat requires review?
Customer

Developed inside an active oncology study site

Clinical partners
Dr. med. Antje Müller
Dr. med. Antje MüllerFounder and lead physicianDas Brustzentrum, Berlin
Angret Wetzel
Angret WetzelStudy coordinatorDas Brustzentrum, Berlin

Mosaic is developed with the physician and study coordinator of Das Brustzentrum, Berlin. The product is tested against real clinical workflows, live study protocols and the team’s existing manual assessment process.

Read the case study
The larger vision

Building the intelligence layer between
patient records and clinical AI

Today, medical knowledge advances separately from the patients who might benefit from it.

Mosaic is building a system in which patient records can be continuously evaluated against new clinical knowledge, and the resulting work can be carried through inside the clinical workflow.

Viktor Kessler, co-founder and CEO of Mosaic
Viktor KesslerCo-founder, CEO
Our mission
Start with one clinical question

See what your patient records can already answer.

Whether you are ready to start a pilot or would rather explore a partnership first, we would love to work with you.

Get in touch